Literature DB >> 16179094

Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.

David Lee.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179094     DOI: 10.1016/S1525-7304(11)70394-1

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  6 in total

Review 1.  Recent advances in the biology of germ cell tumors: implications for the diagnosis and treatment.

Authors:  P Chieffi; S Chieffi; R Franco; A A Sinisi
Journal:  J Endocrinol Invest       Date:  2012-11-12       Impact factor: 4.256

Review 2.  [Value of targeted treatment for testicular cancer: from molecular approaches to clinical possibilities].

Authors:  A Martinschek; C G Ruf; C Sparwasser; H U Schmelz
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

Review 3.  The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

Authors:  Mark W Kieran; Raghu Kalluri; Yoon-Jae Cho
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

Review 4.  Combination of radiotherapy with EGFR antagonists for head and neck carcinoma.

Authors:  Juliette Thariat; Gokcen Yildirim; Kathryn A Mason; Adam S Garden; Luka Milas; K Kian Ang
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

5.  Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines.

Authors:  Jin-Ling Lv; Rui Wang; Dan Liu; Gang Guo; Yong-Kui Jing; Lin-Xiang Zhao
Journal:  Molecules       Date:  2008-06-24       Impact factor: 4.411

Review 6.  Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.

Authors:  Elwyn Cabebe; Heather Wakelee
Journal:  Curr Treat Options Oncol       Date:  2007-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.